Studies on Dibenzylamines as Inhibitors of Venezuelan Equine Encephalitis Virus by Nguyen, Theresa H. et al.
Studies on Dibenzylamines as Inhibitors of Venezuelan Equine
Encephalitis Virus
Theresa H. Nguyen,†,∥ Nicole N. Haese,‡,∥ Nikhil Madadi,† Sanjay Sarkar,§ Kiley Bonin,‡
Cassilyn E. Streblow,‡ Sharon Taft-Benz,§ Nichole A. Tower,∇ Lynn Rasmussen,∇ Robert Bostwick,∇
Corinne E. Augelli-Szafran,† Mark J. Suto,† Thomas E. Morrison,⊥ Victor DeFilippis,‡ Mark T. Heise,§
Daniel N. Streblow,*,‡ and Ashish K. Pathak*,†
†Chemistry Department, Drug Discovery Division, Southern Research, 2000 Ninth Avenue South, Birmingham, Alabama 35205,
United States
‡Vaccine and Gene Therapy Institute, Oregon Health & Science University, 505 NW 185th Avenue, Beaverton, Oregon 97006,
United States
§Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States
∇High-Throughput Screening Center, Drug Discovery Division, Southern Research, 2000 Ninth Avenue South, Birmingham,
Alabama 35205, United States
⊥Department of Immunology and Microbiology, University of Colorado School of Medicine, 12800 E. 19th Avenue, Aurora,
Colorado 80045, United States
ABSTRACT: Alphaviruses are arthropod-transmitted mem-
bers of the Togaviridae family that can cause severe disease in
humans, including debilitating arthralgia and severe neuro-
logical complications. Currently, there are no approved
vaccines or antiviral therapies directed against the alphavi-
ruses, and care is limited to treating disease symptoms. A
phenotypic cell-based high-throughput screen was performed
to identify small molecules that inhibit the replication of
Venezuelan Equine Encephalitis Virus (VEEV). The com-
pound, 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-N-(3-fluoro-
4-methoxybenzyl)ethan-1-amine (1), was identified as a
highly active, potent inhibitor of VEEV with an effective concentration for 90% inhibition of virus (EC90) of 0.89 μM and
7.49 log reduction in virus titers at 10 μM concentration. These data suggest that further investigation of compound 1 as an
antiviral therapeutic against VEEV, and perhaps other alphaviruses, is warranted. Experiments suggested that the antiviral
activity of compound 1 is directed at an early step in the VEEV replication cycle by blocking viral RNA and protein synthesis.
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Alphaviruses, members of the Togaviridae family, arearthropod-borne pathogens responsible for a number of
human and animal diseases.1 These positive-sense single-
stranded RNA viruses are naturally transmitted by infected
mosquitoes to horses, humans, birds, rodents, and other
animals. The New World encephalitic alphaviruses, which
include Venezuelan, Eastern, and Western Equine Encephalitis
Viruses (VEEV, EEEV, and WEEV), cause acute viral
infections in both human and equine populations, mainly
targeting the central nervous system.2 Infection of humans
commonly produces flu-like symptoms, which include sudden
onset of fever, chills, severe headache, sore throat, nausea, and
muscle pain that may progress to fatal encephalitis.3 A small
percentage of VEEV infected humans (14%) experience
neurological symptoms, which occur more frequently in
children than adults,4 and the mortality rate of VEEV is
<1%.5−7 In addition to the natural threat to human health, the
encephalitic alphaviruses can be aerosolized and weaponized;
thus, they could be used as bioterrorism agents. Because of
this, these viruses are classified as category B priority
biodefense agents by the National Institute of Allergy and
Infectious Diseases (NIAID) at NIH.8
Alphaviruses enter cells through receptor-mediated endocy-
tosis and subsequently release the viral genome into the
cytoplasm.9,10 The nonstructural proteins nsP123 and nsP1234
are synthesized first and then quickly form the replication
complex in invaginations at the plasma membrane.11 Virus
minus strand synthesis is driven by a complex containing
nsP123 after nsP4 is released by proteolytic cleavage. The full
length genomic and subgenomic RNA species are synthesized
by fully cleaved nsP1234.12 The subgenomic RNA (sgmRNA)
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is translated into a single polyprotein that is cleaved by both
host and viral proteases into mature structural proteins: capsid,
E3, E2, 6k/TF, and E1. While several advances in the
development of preventative or therapeutic treatments for
VEEV infection have occurred over the past several years,13
there are currently still no Food and Drug Administration
(FDA) licensed vaccines or therapeutic agents against VEEV
or other alphaviruses available for human treatment. Thus, a
critical need exists for the development of a safe and effective
antiviral therapy for these encephalitic viral pathogens.14−17
Here, an approach of developing an efficient small molecule
anti-VEEV compound as a new therapeutic is described.
■ RESULTS AND DISCUSSION
A collaborative drug discovery project was initiated under the
Antiviral Drug Discovery and Development Center
(1U19AI109680; http://www.uab.edu/medicine/ad3c/) to
identify novel small molecules with antiviral activity against
VEEV. A high-throughput screening (HTS) campaign was
designed and conducted on the basis of a previously developed
screen (PubChem: AID 588723).18,19 A VeroE6 cell-based
assay was used to measure the capacity of 197 025 unique
compounds to block VEEV-induced cytopathic effects (CPE)
at a single concentration. From this screen, 940 compounds
were identified to actively inhibit VEEV-induced CPE by
>12%. These 940 compounds were then tested in a 10-point
dose−response CPE assay to determine 50% effective
concentration (EC50) values as well as in a 10-point dose−
response cell viability assay to determine 50% cytotoxicity
concentration (CC50), both performed in the same cell line
used in the HTS. These compounds were further evaluated for
both antiviral activity and cytotoxicity in telomerized human
foreskin fibroblasts (THFFs) to determine EC50 and CC50
values. Antiviral data from both cell lines showed strong
agreement on the activity of these compounds, and 17
compounds were selected for further antiviral activity on the
basis of EC50 (<10 μM) and CC50 (>40 μM) values after Pan
Assay Interference Compounds (PAINS)20 filtration and visual
inspection for any undesirable structural alerts. These 17
compounds were then repurchased for reconfirmation in the
antiviral assay; their purity (high-performance liquid chroma-
tography, HPLC) and integrity (high resolution electrospray
ionization mass spectra, HR-ESIMS, and 1H NMR) were
evaluated, and then, they were subsequently tested in a virus
titer reduction (VTR) assay. The dibenzyl amine compound 1
(Figure 1) showed potent antiviral inhibition with 90%
effective concentration (EC90 = 0.89 μM) and 7.49 log of
VTR at 10 μM concentration with no cytotoxicity up to 30 μM
concentration using THFF cells. Hence, this hit compound
was selected for lead optimization. In addition, compound 1
also underwent mode-of-action mechanistic studies against
VEEV to aid lead generation and optimization studies.
Hit-to-Lead Chemistry. The design and synthesis of novel
inhibitors of VEEV were the focus for identifying potent,
noncytotoxic analogs of compound 1 with desirable drug-like
properties, including solubility (≥10 μM), LogD (2−4), and
microsomal stability (human liver microsomes (HLM) and
mouse liver microsomes (MLM) = t1/2 ≥ 60 and ≥30 min,
respectively). Due to the efficacious (VTR ≥ 3 log), potent
(EC90 ≤ 1 μM), and noncytotoxic (CC50 ≥ 30 μM) properties
of compound 1, solubility (in pH 7.4 buffer) and microsomal
stability [human (HLM) and mouse (MLM)] analyses were
conducted to define starting in vitro physiochemical and
absorption, distribution, metabolism, and excretion (ADME)
parameters of this hit compound. Compound 1 showed
acceptable solubility of 65 μM with poor half-life (t1/2) in
human (HLM) and mouse (MLM) liver microsomes of 8 and
2 min, respectively. In addition, StarDrop calculations were
implemented using cytochrome P450 metabolism predictions
to calculate the composite site liability (CSL) and identify
metabolically unstable areas in compound 1. The calculated
CSL values are used as a measure of the metabolism efficiency
of a molecule by seven of the major drug metabolizing
isoforms of CYP. Figure 2 highlights the most prominent labile
sites of compound 1 as the two benzylic positions and the
methoxy group (labeled in red). The methylenes of the
dioxane moiety labeled in yellow were predicted to be
moderately labile. The structure−activity relationship (SAR)
studies involved three areas of compound 1, which are
indicated in Figure 2 as yellow, red, and green. Modifications
to these areas would be to improve microsomal stability while
retaining the antiviral activity and potency.
We first wanted to determine the requirement of the 1,4-
dioxane ring located in the left-hand portion of the compound.
Analogs 4 and 5 (Table 1, entries 2 and 3) were designed to
determine whether removal or ring opening of the dioxane
moiety was tolerated. The synthesis of these dibenzyl amine
analogs 4 and 5 was accomplished in moderate yields via a
substitution reaction of the appropriate benzyl amine 2 and
benzyl bromide 3 in the presence of K2CO3 with conventional
heating (Scheme 1, eq 1). Analogs 4 and 5 were tested for
antiviral activity against VEEV in a VTR assay using normal
human dermal fibroblast (NHDF) cells at 10 μM concen-
tration. Neither of these 2 analogs showed >2 log for VTR,
which suggests that a bicyclic ring system may be required for
Figure 1. Structure, antiviral activity, and cellular cytotoxicity of
compound 1.
Figure 2. StarDrop predictions for composite site liability,
experimental solubility, and LogD of compound 1. Composite site
liability (CSL) is a measure of metabolism efficiency of a compound
by an isoform (e.g., CYP3A4). CSL values are between 0 and 1, with
the lower values indicating greater metabolic stability by a CYP
isoform. Red = very labile, yellow = moderately labile, and green =
slightly labile.
antiviral activity. Hence, EC90’s were not determined (Table 1,
entries 2 and 3). The scope of the bicyclic ring system of
compound 1 was examined by evaluating various rings, such as
fused cyclohexyl-, pyran-, and morpholino-phenyl rings,
compounds 6, 10, and 11, respectively (Scheme 1).
Compound 6 was prepared in a similar fashion as compound
4 (Scheme 1, eq 1), while compounds 10 and 11 were
prepared via reductive amination of the desired ketone 7 or 8
with 3-fluoro-4-methoxybenzylamine (9), respectively
(Scheme 1, eq 2). Compound 6 showed an efficacy of 3.2
log at 10 μM in the VTR assay and possessed EC90 of 1.2 μM,
which is very comparable to compound 1. However, no
improvement was seen in microsomal stability versus
compound 1 (MLM t1/2 = 3 min) (Table 1, entry 4).
Although analogs 10 and 11 showed very high VTR (∼7.7 log
at 10 μM), the EC90 increased 3-fold versus compound 1, and
there was no significant improvement in MLM values (Table 1,
entries 5 and 6). As these minor modifications failed to
improve both the antiviral activity and microsomal stability,
our SAR efforts shifted to examining the right-hand portion of
compound 1.
Table 1. Antiviral Evaluation of Analogs against VEEV and in Vitro ADME Dataa
aVTR = virus titer reduction; EC90 = antiviral inhibition with 90% effective concentration; CC50 = 50% cytotoxicity concentration; MLM t1/2 =
half-life in mouse liver microsomes.
Scheme 1. General Routes to Dibenzyl Amine Derivativesa
aReagents and conditions: (a) K2CO3, DMF, 50−80 °C, 16 h, 11−
79%; (b) para-toluenesulfonic acid (p-TSA), toluene, reflux, 12−16 h,
then NaBH3CN or lithium aluminum hydride (LAH), overnight, then
H2, Pd/C, MeOH, 26−87%.
Thus, analogs centered on preserving the left-hand dioxane
phenyl moiety while replacing the right benzyl group with
monosubstituted benzyl derivatives were evaluated. Com-
pounds 14−18 (Table 1, entries 7−11) were synthesized in a
single step nucleophilic substitution from benzyl amine 12 and
the appropriate benzyl halides in low-to-moderate yields
(Scheme 1, eq 3). Elimination of the 4-methoxy group to
afford the meta-fluoro benzyl analog 14 provided a VTR of 6.1
log at 10 μM. However, potency was reduced by 3-fold (EC90
of 3.1 μM; Table 1, entry 7). Replacing the meta-fluoro
substituent on the phenyl ring with electron-withdrawing or
electron-donating substituents, such as CF3 (15) and OMe
(16), was not well-tolerated, and antiviral potency decreased
by 11-fold (Table 1, entries 8 and 9). Likewise, migrating the
fluoro-substituent from the meta- to the para-position in
compound 17 and the p-t-butylbenzyl substitution in
compound 18 also resulted in a loss of antiviral activity by
11-fold (Table 1, entries 10 and 11).
Since modifying the left-and right-hand rings of compound 1
afforded no improvement in anti-VEEV activity or in
microsomal stability, the middle ring of compound 1 was
then explored. Since the benzylic positions of compound 1
were indicated by the StarDrop P450 calculations (Figure 2) to
be labile sites, compounds 19−24 were designed to address
this. The scope for cyclizing the left- and right-hand benzylic
moieties included tetraisoquinoline 19 and indole derivatives
20 and 21 (Figure 3). Likewise, cyclizing the two benzylic
moieties into nitrogen containing rings afforded analogs such
as pyridine 22, piperidine 23, and thiazole 24 (Figure 3). Initial
VTR studies on analogs 19−24 showed no antiviral activity
(<1 log) at 10 μM concentration.
The observed loss of potency with cyclizing any of the three
structural components in the middle portion of the molecule
guided our attention toward investigating analogs with
modification of the benzylic functionality. The presence of
the benzyl components was highlighted in analogs 28, 29, and
30 by removal of both benzyl positions or select removal of the
right benzyl or left benzyl position, respectively. These analogs
were readily synthesized via a Buchwald-Hartwig amination of
the corresponding amine and aryl halide (Scheme 2, eq 1).
Condensing the center amine linker via elimination of one or
both benzyl components resulted in no antiviral potency (VTR
≤ 1 log at 10 μM concentration), thus emphasizing the
importance of retaining the benzylic functionality toward
antiviral activity.
We studied an alternative strategy of blocking the right
benzyl moiety with various substitutions including analogs that
possess a sulfonyl (33), carbonyl (34), and cyclopropyl (37)
group in order to increase metabolic stability pertaining to the
benzyl moiety. Synthesis of sulfonamide 33 was completed via
a substitution of benzyl amine 12 and sulfonyl chloride 31 in
the presence of triethylamine in 50% yield (Scheme 2, eq 2).
Incorporating a carbonyl to give amide 34 was achieved via a
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]-
pyridinium 3-oxide hexafluorophosphate(HATU) mediated
coupling of amine 12 and carboxylic acid 32 (Scheme 2, eq
2), while dibenzyl amine 37, bearing a cyclopropyl, was
prepared via reductive amination of ketone 35 and cyclo-
propylamine 36 (Scheme 2, eq 3). Lack of potency (VTR ≤ 1
log at 10 μM concentration) and poor microsomal stability
(MLM t1/2 < 1 min) were observed in all three analogs. Since
we were unable to resolve the issue of microsomal stability by
modifying the predicted labile sites calculated in StarDrop, we
investigated the potential metabolites of compound 1 using
high resolution mass spectroscopy. The major metabolite was
identified as a hydroxy analog in which a hydroxyl group is
inserted at the left benzyl position; thus, a methyl group was
incorporated in the left benzyl position to stabilize the
molecule. The gem-dimethyl analog 39 was prepared by
converting methyl ketone 31 to tertiary amine 38 over three
steps (39% yield) followed by a substitution reaction with the
desired 3-fluoro-4-methoxybenzyl bromide in 56% yield
(Scheme 2, eq 4). Compound 39 showed excellent antiviral
efficacy (VTR = 9.1 log at 10 μM) and improved potency by 2-
fold (EC90 = 0.38 μM) against VEEV; however, increased
cytotoxicity (CC50 = 15 μM) and poor metabolic stability were
noted (Table 1, entry 12). A similar gem-dimethyl analog 40,
prepared similarly described for compound 39, in which the
right benzyl moiety was removed, exhibited high antiviral
potency (EC90 = 0.37 μM) and efficacy (VTR = 4.9 log at 10
μM) with no toxicity observed up to a 30 μM concentration
(Table 1, entry 13). However, analog 40 displayed poor
microsomal stability (MLM t1/2 < 1 min), further indicating
that insertion of the gem-dimethyl moiety on the left benzylic
group and complete removal of the right benzyl moiety did not
improve microsomal stability.
Antiviral Breadth and Mechanism of Action. To assess
the antiviral breadth of compound 1, we compared the antiviral
activity in cells from two different relevant species: humans
(NHDF) and mosquitos (Aedes albopictus C6/36). A 10-point
dose response assay was performed with compound concen-
trations ranging from 100 to 0.19 μM. Compound 1 was added
to NHDF cells and C6/36 cells 1 h prior to infection with
VEEVTC83 with a multiplicity of infection (MOI) of 1 (Figure
4). At 2 h postinfection (hpi), cells were washed and fresh
medium was added containing compound 1. Culture super-
natants were collected at 24 hpi, and infectious virus was
quantified by standard plaque assays. Compound 1 reduced
viral titers to background levels at 6.25 μM in human
fibroblasts and maximally reduced virus titers by >2 log in
C6/36 cells with CC50 > 40 μM (Figure 4), indicating
compound activity in both cell types. Next, we evaluated the
antiviral breadth of compound 1 by treating NHDF cells with
dimethyl sulfoxide (DMSO) or compound 1 at 1 or 10 μM 1 h
prior to infection with other human alphaviruses including
Chikungunya virus (CHIKV) at MOI = 1, O’nyong nyong
Figure 3. Scope of heterocyclic-containing analogs to stabilize the
benzylic moiety.
virus (ONNV) at MOI = 2, Ross River virus (RRV) at MOI =
2, Una virus (UNAV) at MOI = 2, and Mayaro virus (MAYV)
at MOI = 2. At 2 hpi, cells were washed and fresh medium with
compound 1 was added. Supernatants from the infected cells
were collected at 24 hpi for infectious virus quantification by
plaque assays. Compound 1 failed to elicit any significant
inhibitory effect against CHIKV, ONNV, RRV, UNAV, and
MAYV (Figure 5).
To determine the step(s) in the VEEV life cycle that are
affected by compound 1 treatment, a time of compound
addition experiment was performed. In this assay, production
of infectious virus was quantified in supernatants from NHDF
cells infected with VEEV (MOI = 1) treated with compound 1,
the inactive analog (compound 5), or DMSO at 0, 2, 4, 6, 8,
Scheme 2. Synthetic Route of Analogs with Modification of the Benzyl Functionalitya
aReagents and conditions: (a) Pd2dba3, BrettPhos, K−OtBu, toluene, 80 °C, 16 h, 34−82%; (b) TEA, DCM, 3 h, 50%; (c) HATU, DIPEA, DMF,
16 h, 19%; (d) p-TSA, toluene reflux, 12 h, then NaBH4, 16 h, 12%; (e) MeMgBr/THF, −78 °C, 16 h, 85%; (f) NaN3, TFA, DCM, 12 h, 49%; (g)
H2 Pd/C, MeOH, overnight, 94%; (h) 3-fluoro-4-methoxybenzyl bromide, K2CO3, DMF, 80 °C, 12 h, 56%; (i) 27, Pd2dba3, BrettPhos, K−OtBu,
toluene, 80 °C, 16 h, 34%.
Figure 4. Antiviral activity of compound 1 in (A) NHDF cells and
(B) Aedes albopictus C6/36 cells. Cells were pretreated for 1 h with
DMSO or 2-fold serial dilutions of compound 1 ranging from 100 to
0.2 μM. Treated cells were infected with VEEVTC83 at an MOI of 1 in
the presence of compound. At 2 hpi, the culture media was removed
and the cells were washed once with PBS. Medium containing
compound was replenished, and supernatants were collected 24 hpi;
infectious virus was quantified by the plaque assay on Vero cells. The
data is graphed as the mean, and error bars represent the standard
deviation. IC90 values were calculated using Prism software and is
representative of three independent experiments.
Figure 5. Breadth of antiviral activity of compound 1. NHDF cells
were pretreated for 1 h with DMSO or compound 1 at 10 or 1 μM.
Treated cells were then infected with CHIKV181‑25, MAYVTRVL
ONNV, RRV, or UNAVMAC150 in the presence of compound. At 2
hpi, culture medium was removed; cells were washed once with PBS,
and medium containing compound was added. Supernatants were
collected 24 hpi, and infectious virus was quantified by the plaque
assay on Vero cells after 48 h of incubation (n = 3). Mean titers and
standard deviation are graphed. The data is representative of two
independent experiments.
and 10 hpi. Treatment of CHIKV infected cells was included
as a control. Compound 1 reduced VEEV production by nearly
3 log when added at all time points (0−10 hpi) (Figure 6).
Treatment of infected cells with compound 5 or DMSO failed
to affect VEEV infectious virus production. CHIKV was
unaffected by compounds 1 and 5.
To further define the stage where compound 1 blocks VEEV
replication, a VEEV replicon particle (VRP) based on a vaccine
strain of the Trinidad donkey strain of VEEV (VEE 3526) was
used as described previously.21 These VRPs consists of VEE
3526 replicon RNA encoding the replicase proteins and a 26S
promoter from which GFP is expressed. VRPs can undergo
only one round of replication and cannot form progeny VRPs
from the infected cells. Therefore, if compound 1 blocks GFP
expression, this would indicate that the drug acts on the viral
lifecycle prior to viral 26S RNA translation. Human embryonic
kidney 293T cells (HEK-293T) were pretreated with either
compound 1 or 3 (1, 5, and 10 μM) or DMSO for 1 h and
then infected with VRP at an MOI of 1 PFU/cell. At 8 hpi,
cells were washed and fixed with 4% paraformaldehyde and
analyzed by flow cytometry. Compound 1 reduces the
percentage of GFP-expressing cells compared to DMSO-
treated cells (Figure 7A). Consistent with prior results, the
inactive compound 5 had no effect on replicon gene
expression. These results indicate that compound 1 inhibits
translation of the 26S subgenomic RNA or a step prior to this
event. Next, we bypassed the entry step of the VRPs by
transfecting HEK-293T cells with replicon RNA in the
presence of DMSO or compound 1 or 5. At 24 hpi, cells
were washed, fixed, and analyzed by flow cytometry for the
expression of GFP. Compound 1 significantly reduced the
number of VRP-GFP positive HEK-293T cells compared to
DMSO or compound 5 (Figure 7B). In addition, compound 1
treatment caused a marked reduction of mean fluorescence
intensity (MFI) of the VRP-GFP positive cells, indicating that
compound 1 treatment inhibited expression of VRP genes
(Figure 7C). Therefore, bypassing entry does not rescue viral
gene expression in the presence of compound 1, which
indicates that the compound inhibits VEEV replication at a
postentry step.
To further identify the step in viral replication affected by
compound 1, we examined VEEV RNA and protein
production in cells treated with the compound. Northern
blotting analysis was used to determine the effect of the
compound on accumulation of the 49s (genomic) and 26s
(subgenomic) VEEV RNA species at 12 hpi. NHDF cells were
pretreated with DMSO or 10 μM of compound 1 or 5 for 1 h
prior to infection with VEEVTC83 (MOI = 5). At 2 hpi, cells
were washed and fresh media containing compound was added
to the cells. Total RNA was isolated from the cells using
TRIzol reagent at 12 hpi, separated on a 1% formaldehyde
agarose gel, and transferred to an N+ membrane by capillary
transfer. The membrane was hybridized with a DIG-labeled
RNA probe specific for a 1 kb fragment of the VEEV RNA
segment present in both the 26s and 49s RNA species as well
as a loading control probe directed against a 1 kb fragment of
human β-actin. Probe binding was visualized after staining with
an anti-DIG antibody followed by incubation with a CSPD
alkaline phosphatase substrate. Compound 1 treatment
abolished the accumulation of both 49s and 26s VEEV RNA
species in comparison to control DMSO-treated and
compound 5-treated cells, indicating compound 1 blocks
viral RNA synthesis (Figure 8). As expected, due to the block
in viral RNA synthesis, compound 1 also inhibited VEEV
structural protein expression (capsid and glycoprotein) as is
evident from the Western blotting analysis of the cell lysates
Figure 6. Compound 1 time of drug addition assay. NHDF cells were
infected with VEEVTC83 or CHIKV181‑25 at an MOI = 1 and treated
with DMSO, 10 μM compound 1, or 10 μM compound 5 at 0, 2, 4, 6,
8, and 10 hpi. Supernatants were collected at 24 hpi, and infectious
virus was quantified by the plaque assay on Vero cells (n = 3). Mean
and standard deviation (error bars) are graphed. The data is
representative of two independent experiments.
Figure 7. Effect of compound 1 on VEEV entry. (A) HEK-293T cells were pretreated with compound 1 at 1, 5, or 10 μM, compound 5 at 10 μM,
or DMSO for 1 h and then infected with VRP-GFP at an MOI of 1. At 8 hpi, cells were washed and fixed with 4% PFA and analyzed by flow
cytometry. (B, C) HEK-293T cells were pretreated with compounds as in (A) and transfected with in vitro transcribed VRP RNA. At 24 hpt, cells
were fixed in 4% PFA and analyzed by flow cytometry. The figure represents the mean with the standard deviation from one of three independent
experiments performed in triplicate.
prepared from the VEEV infected Vero cells at 12 hpi (Figure
9A−C). An immunofluorescence assay was performed on the
Vero cells infected with VEEVTC‑83 in the presence of
compound 1, which also showed inhibition of VEEV
glycoprotein expression (Figure 9D). In both WB and IFA,
compound 5 and DMSO treatment did not block VEEV
protein synthesis.
To further confirm the effect of compound 1 on viral gene
expression, we generated two VEEVTC83 reporter viruses
expressing NanoLuc (nLuc; 513 nt; Promega) as a fusion
with either nsP3 (TC83 nsP3-nLuc) or between capsid and
PE2 (TC83-Cap-nLuc) using approaches similar to those
described by Sun et al.22 These reporter viruses allow us to
monitor expression of both the viral nonstructural proteins and
structural proteins. Vero cells were pretreated with DMSO or
compound 1 or 5 for 1 h before being infecting with TC83
nsP3-nLuc or TC83-Cap-nLuc viruses (MOI = 5). At 12 hpi,
cells were washed twice with cold PBS and lysed using the
Nano-Glo Luciferase Assay system (Promega). Consistent with
the replicon and Western blot results (Figures 7 and 9),
compound 1 blocked expression of the capsid NanoLuc fusion
TC83-Cap-nLuc (Figure 10A). Furthermore, compound 1
treatment markedly reduced luminescence in TC83 nsP3-nLuc
virus infected cells compared to DMSO and compound 5
treated infected cells (Figure 10B). These results indicated that
compound 1 acts either by blocking early viral RNA
amplification or by blocking viral nonstructural protein
translation.
Figure 8. Compound 1 treatment inhibits VEEVTC83 49s and 26s
RNA accumulation. NHDF cells were pretreated for 1 h with DMSO,
10 μM compound 1, or 10 μM compound 5. Treated cells were then
infected with VEEVTC83 at an MOI of 5 in the presence of compound.
At 2 hpi, cells were washed with PBS and medium containing
compounds was added. Cell lysates collected at 12 hpi in trizol; RNA
was isolated and analyzed by Northern blot for 49s and 26s VEEV
RNA levels using VEEV specific DIG labeled probes and the control
human β-actin probe (n = 3, best representative image).
Representative image of three technical replicates.
Figure 9. Effect of compound 1 on VEEV protein synthesis. Vero cells were pretreated with compound 1 (1, 5, and 10 μM), compound 5 (10 μM),
or DMSO for 1 h before infection with VEEVTC‑83 at an MOI = 5. At 2 hpi, cells were washed and medium containing compounds was added. At
12 hpi, cells were either lyzed for Western blot analysis with (A) anti-VEEV GP, (B) anti-VEEV capsid, and (C) control β-actin antibodies or (D)
fixed for indirect immunofluorescence assay using anti-VEEV GP antibody. The figure is representative of three independent experiments.
Figure 10. Compound 1 inhibits protein synthesis of nonstructural
and structural genes fused inframe with nLuc. Vero cells were
pretreated with compound 1 (10 μM), compound 5 (10 μM), or
DMSO for 1 h prior to infection with recombinant VEEV expressing
nLuc (A) TC83 nsP3-nLuc and (B) TC83-Cap-nLuc at MOI = 5.
Cells were washed with PBS at 2 hpi, and medium containing
compounds was added. At 12 hpi, cells were lysed and Nano-Glo
luciferase assays were performed. The figure represents the mean with
the standard deviation from one of three independent experiments
performed in triplicate.
■ CONCLUSIONS
Currently, there are no FDA licensed vaccines or therapeutics
targeting the encephalitic alphaviruses for use in humans. Since
members of this virus family are in circulation and have the
potential for outbreaks that would cause devastating neuro-
logical outcomes, there is a great need for the development of
antivirals directed against alphaviruses. Herein, we have
designed and synthesized analogs of compound 1 as potential
VEEV replication inhibitors. SAR studies were completed,
which evaluated three areas of compound 1. In pursuit of the
lead optimization of hit compound 1, a few selected analogs
showed an improved activity profile, including low cytotoxicity
and high potency and efficacy. However, the challenge of
addressing microsomal stability in these analogs was
unresolved. Ultimately, compound 40 showed an increase in
potency by 2-fold in comparison to compound 1 (EC90 = 0.37
μM, VTR = 4.9 log at 10 μM) with no cytotoxicity (CC50 > 30
μM). However, poor microsomal stability was observed (MLM
< 1 min). Target identification and mechanism of action
studies were also conducted. Compound 1 blocked virus
replication at an early step in the virus lifecycle postbinding
and entry. The compound blocked viral RNA and protein
accumulation indicative of a block in nonstructural protein
function. However, generation of a resistant virus to compound
1 was unsuccessful, which might indicate that compound 1
targets an essential viral component or a host function critical
for virus replication. Continued studies to address the
challenging issue of metabolic stability while retaining potency
and efficacy and to determine the specific mechanism of action
for compound 1 are ongoing.
■ EXPERIMENTAL SECTION
General Chemistry. The reactions were performed under
a dry argon atmosphere, and reaction temperatures were
measured externally. Anhydrous solvents over molecular sieves
were purchased from Aldrich and used as such in reactions.
Microwave (MW) reactions were performed in the CEM
Discover Labmate System with Intelligent Technology for
Focused Microwave Synthesizer (Explorer 48). The reactions
were monitored by thin-layer chromatography (TLC) on
precoated silica gel (60F254) aluminum plates (0.25 mm) from
E. Merck and visualized using UV light (254 nm). Purification
of the compounds was performed on an Isco Teledyne
Combiflash Rf200. Universal RediSep solid sample loading
prepacked cartridges (5.0 g silica) were used to absorb crude
product and purified on 12 g silica RediSep Rf Gold Silica
(20−40 μm spherical silica) columns using appropriate solvent
gradients. Pure samples were dried overnight under high
vacuum before analyses. The high resolution electrospray
ionization mass spectral data (HR-ESIMS) were obtained on
an Agilent LC-MSTOF. 1H NMR spectra were recorded at
400 MHz on an Agilent/Varian MR-400 spectrometer with
CDCl3, CD3OD, or DMSO-d6 as solvents. The chemical shifts
(δ) are in ppm downfield from standard tetramethylsilane
(TMS). HPLC analyses of the final compounds were run on an
Agilent 1100 LC equipped with a diode array UV detector and
were monitored at 254 and 280 nm using the following
methods: Method A = Kinetix 5 μ C18, 150 × 4.6 mm column
using Solvent A, 0.1% trifluoroacetic acid (TFA) in H2O;
Solvent B, 0.1% TFA in MeCN; flow rate, 1.0 mL/min; 20 min
linear gradient from 5% to 95% B; hold for 2 min and then
back to 95% A over 3 min. Method B = SunFire C18 5 μm, 4.6
× 150 mm column using Solvent A, 0.1% TFA in H2O; Solvent
B, 0.1% TFA in MeCN; flow rate, 2.0 mL/min; 15 min linear
gradient from 10% to 90% B and then back to 10% B over 0.1
min and held for 4.9 min. Method C = Kinetix 5 μ C18, 150 ×
4.6 mm column using Solvent A, H2O; Solvent B, MeCN; flow
rate, 1.0 mL/min, 15 min linear gradient from 10% to 90% B
and then held for 5 min. Method D = Kinetix 5 μ C18, 150 ×
4.6 mm column using Solvent A, H2O; Solvent B, MeCN; flow
rate, 1.0 mL/min; 20 min linear gradient from 5% to 95% B,
hold for 2 min and then back to 95% A over 3 min. Method E
= Kinetix 5 μ C18, 150 × 4.6 mm column using Solvent A,
0.1% HCO2H in H2O; Solvent B, 0.1% HCO2H in MeCN;
flow rate, 1.0 mL/min; 20 min linear gradient from 0% to 90%
B; hold for 2 min and then back to 100% A over 3 min.
General Procedure 1 (GP1). A mixture of amine or amine-
HCl salt (1 equiv), benzyl bromide (1 equiv), and K2CO3 (1−
2 equiv) in anhydrous dimethylformamide (DMF; 0.25 M)
was heated overnight at 50−70 °C. The reaction was cooled to
room temperature, diluted with H2O (15 mL), and extracted
with EtOAc (3 × 10 mL). Combined organic layers were
washed with brine (10 mL), dried over anhydrous Na2SO4,
filtered, and concentrated in vacuo.
General Procedure 2 (GP2). To an oven-dried, 25 mL
round-bottom flask were added indole/benzimidazole (1
equiv) and sodium hydride (60% dispersion in mineral oil;
1.1 equiv) under argon. The flask was evacuated and filled with
argon three times followed by the addition of 6-(bromometh-
yl)-2,3-dihydrobenzo[b][1,4]dioxine (1.1 equiv) and DMF (2
mL). After stirring overnight at room temperature, the reaction
was quenched with saturated NH4Cl and extracted with
dichloromethane (DCM; 3 × 10 mL). Combined organic
layers were dried over anhydrous Na2SO4, filtered, and
concentrated under vacuum.
General Procedure 3 (GP3). To a 25 mL Schlenk flask with
a stir bar were added Pd2(dba)3 (1 mol %), BrettPhos (3 mol
%), and KOtBu (1.5−2.5 equiv). The flask was evacuated and
filled with argon three times, followed by addition of amine
(1.3 equiv), aryl bromide (1 equiv), and anhydrous toluene
(0.3 M). The flask was sealed, heated at 80 °C, and stirred
overnight. Upon completion, the reaction was diluted with
EtOAc, filtered through a short pad of silica gel, and
concentrated in vacuo.
General Procedure 4 (GP4). Using a Dean−Stark apparatus,
ketone (1 equiv), benzyl amine (1 equiv), and p-
toluenesulfonic acid monohydrate (0.1 equiv) were refluxed
in anhydrous toluene or tetrahydrofuran (THF; 0.2 M) for
12−16 h. After imine formation, confirmed via mass spectra,
the reaction was concentrated in vacuo and dried under high
vacuum. The appropriate reducing agent was then used in the
subsequent step as described below.
1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-N-(3-fluoro-4-
methoxybenzyl)ethan-1-amine (1). 1 was purchased from
Enamine (Z139650624). 1H NMR (400 MHz, DMSO-d6) δ
7.35 (d, J = 12.3 Hz, 1H), 7.20 (dd, J = 4.5, 1.3 Hz, 2H), 7.08
(s, 1H), 6.97 (d, J = 8.7 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H),
4.26 (s, 4H), 4.24 (s, 1H), 3.98 (s, 1H), 3.85 (s, 3H), 3.77 (s,
1H), 1.54 (d, 3H). HR-ESIMS (m/z): calcd for C18H21FNO3
(M + H)+ 318.15; found 318.1497. HPLC purity = 98%
(Method A; retention time (tR) = 9.65 min).
N-(3-Fluoro-4-methoxybenzyl)-1-phenylethan-1-amine
(4). Following GP1 with 4-(bromomethyl)-2-fluoro-1-methox-
ybenzene (110 mg, 0.5 mmol) and 1-phenylethanamine (64
μL, 0.5 mmol), the resulted product was purified via flash
chromatography (0−15% EtOAc/hexanes) to give the desired
compound 4 (102 mg, 79%) as a light-yellow oil. 1H NMR
(400 MHz, CD3OD) δ 7.37−7.29 (m, 4H), 7.25 (dddt, J =
8.4, 5.6, 3.2, 1.6 Hz, 1H), 7.06−6.91 (m, 3H), 3.84 (d, J = 0.9
Hz, 3H), 3.76−3.68 (m, 1H), 3.47 (q, J = 13.1 Hz, 2H), 1.35
(dd, J = 6.7, 1.0 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ
154.75, 152.31, 147.98, 145.71, 133.90, 133.85, 129.60, 128.21,
127.91, 125.47, 125.44, 117.06, 116.88, 114.50, 58.36, 56.71,
56.67, 51.21, 51.19, 23.85. HR-ESIMS (m/z): calcd for
C16H19FNO (M + H)
+ 260.1445; found 260.1443. HPLC
purity = 100% (Method B; tR = 3.91 min).
1-(3,4-Dimethoxyphenyl)-N-(3-fluoro-4-methoxybenzyl)-
ethan-1-amine (5). Following GP1 with 4-(bromomethyl)-2-
fluoro-1-methoxybenzene (110 mg, 0.5 mmol) and 1-(3,4-
dimethoxyphenyl)ethanamine hydrochloride (109 mg, 0.5
mmol), the resulted product was purified via flash chromatog-
raphy (0−33% EtOAc/hexanes) to give the desired compound
5 (100 mg, 63%) as a yellow oil. 1H NMR (400 MHz,
CD3OD) δ 7.08−6.93 (m, 4H), 6.91 (d, J = 8.2 Hz, 1H), 6.83
(dt, J = 8.4, 1.4 Hz, 1H), 3.83 (dd, J = 2.3, 1.0 Hz, 6H), 3.82
(d, J = 0.9 Hz, 3H), 3.68 (q, J = 6.7 Hz, 1H), 3.48 (q, J = 13.2
Hz, 2H), 1.34 (dd, J = 6.7, 1.0 Hz, 3H). 13C NMR (100 MHz,
CD3OD) δ 154.71, 152.28, 150.67, 149.56, 148.03, 138.64,
134.04, 133.99, 125.48, 120.54, 117.08, 117.07, 116.89, 114.50,
112.91, 111.44, 58.08, 56.71, 56.67, 56.51, 56.47, 56.41, 56.37,
51.20, 23.90. HR-ESIMS (m/z): calcd for C18H23FNO3 (M +
H)+ 320.1656; found 320.1645. HPLC purity = 98% (Method
B; tR = 3.78 min).
N-(3-Fluoro-4-methoxybenzyl)-1-(5,6,7,8-tetrahydro-
naphthalen-2-yl)ethan-1-amine (6). Following GP1 with 4-
(bromomethyl)-2-fluoro-1-methoxybenzene (110 mg, 0.5
mmol) and 1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanamine
(87 μL, 0.5 mmol), the resulted product was purified via flash
chromatography (0−15% EtOAc/hexanes) to give the desired
compound 6 (91 mg, 58%) as a yellow oil. 1H NMR (400
MHz, CD3OD) δ 7.05−6.87 (m, 6H), 3.83 (s, 3H), 3.63 (q, J
= 6.6 Hz, 1H), 3.54−3.38 (m, 2H), 2.74 (q, J = 5.5 Hz, 4H),
1.79 (m, J = 4.3 Hz, 4H), 1.32 (d, J = 6.6 Hz, 3H). 13C NMR
(100 MHz, CD3OD) δ 154.77, 152.34, 148.07, 142.68, 138.14,
136.95, 134.09, 134.03, 130.25, 128.55, 125.48, 125.45, 125.03,
117.11, 116.93, 114.50, 58.14, 56.74, 56.69, 51.21, 30.48,
30.11, 24.49, 23.80. HR-ESIMS (m/z): calcd for C20H25FNO
(M + H)+ 314.1915; found 314.1911. HPLC purity = 100%
(Method B; tR = 5.99 min).
1-(Chroman-6-yl)-N-(3-fluoro-4-methoxybenzyl)ethan-1-
amine (10). GP4 was followed with 1-(chroman-6-yl)ethanone
7 (70 mg, 0.4 mmol), (3-fluoro-4-methoxyphenyl)-
methanamine (55 μL, 0.4 mmol) 9, and p-toluenesulfonic
acid monohydrate (7.6 mg, 0.04 mmol). To the resulted imine
in dichloroethane (1 mL) were added acetic acid (0.4 mL, 6.99
mmol) and sodium cyanoborohydride (71 mg, 1.1 mmol) at 0
°C under argon, and the mixture was stirred overnight. Upon
completion, monitored via TLC, the reaction was quenched
with saturated NaHCO3 (3 mL) and then extracted with
EtOAc (3 × 5 mL). The combined organic layer was dried
over anhydrous Na2SO4, filtered, and concentrated in vacuo.
The product was purified via flash chromatography (0−9%
MeOH/DCM) to give the desired compound 10 (62 mg,
87%) as a clear sticky oil. 1H NMR (400 MHz, CDCl3) δ
7.14−6.93 (m, 5H), 6.84 (d, J = 8.4 Hz, 1H), 4.25−4.17 (m,
2H), 4.09 (q, J = 6.8 Hz, 1H), 3.92−3.83 (m, 4H), 3.77 (d, J =
13.3 Hz, 1H), 2.82 (t, J = 6.4 Hz, 2H), 2.08−2.03 (m, 2H),
1.67 (d, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ
155.99, 153.24, 150.77, 148.53, 129.14, 126.81, 126.53, 126.38,
123.56, 117.69, 117.61, 117.42, 113.80, 66.68, 58.42, 56.26,
48.82, 29.68, 24.85, 21.97, 20.22. HR-ESIMS (m/z): calcd for
C19H23FNO2 (M + H)
+ 316.1707; found 316.1711. HPLC
purity = 94% (Method A; tR = 10.43 min).
1-(3,4-Dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-(3-fluoro-
4-methoxybenzyl)ethan-1-amine (11). GP4 was followed
with 6-acetyl-2H-benzo[b][1,4]oxazin-3(4H)-one (76 mg, 0.4
mmol) 8, (3-fluoro-4-methoxyphenyl)methanamine 9 (55 μL,
0.4 mmol), and p-toluenesulfonic acid monohydrate (7.6 mg,
0.04 mmol). The resulted amide intermediate was dissolved in
anhydrous THF (4 mL) without purification followed by
lithium aluminum hydride (0.038 g, 1 mmol) addition under
argon at −78 °C. The reaction mixture was warmed to room
temperature with stirring and further refluxed overnight. The
reaction mixture was cooled to 0 °C and quenched with water
(0.5 mL) and then 10% NaOH (0.5 mL). The mixture was
filtered through Celite, and the filtrate was concentrated in
vacuo. The residue was extracted with DCM (3 × 5 mL), dried
over anhydrous Na2SO4, filtered, and concentrated in vacuo.
To a hydrogenation bottle was added the crude imine
intermediate in MeOH (2 mL). Under an argon atmosphere,
10 mol % Pd/C (21.3 mg, 0.02 mmol) was quickly added to
the hydrogenation bottle; it was then capped and placed on the
hydrogenator. The reaction was run at 38 psi overnight; it was
then filtered through Celite, rinsed well with MeOH, and
concentrated in vacuo. The product was purified via flash
chromatography (0−5% MeOH/DCM + 0.3% triethylamine,
TEA) to give the desired compound 11 (33 mg, 26%) as a
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.05 (dd, J = 12.2,
2.1 Hz, 1H), 6.99−6.94 (m, 1H), 6.88 (t, J = 8.4 Hz, 1H), 6.74
(d, J = 8.1 Hz, 1H), 6.63−6.57 (m, 2H), 4.28−4.22 (m, 2H),
3.87 (s, 3H), 3.64 (q, J = 6.6 Hz, 1H), 3.61−3.49 (m, 2H),
3.45−3.40 (m, 2H), 1.32 (d, J = 6.6 Hz, 3H). 13C NMR (100
MHz, CDCl3) δ 153.50, 151.06, 146.46, 146.35, 143.11,
138.04, 133.54, 123.75, 123.71, 117.18, 116.53, 116.02, 115.84,
113.56, 113.21, 113.19, 65.23, 56.91, 56.33, 56.32, 50.52,
41.01, 24.28. HR-ESIMS (m/z): calcd for C18H22FN2O2 (M +
H)+ 317.1659; found 317.1661. HPLC purity = 95% (Method
B; tR = 4.04 min).
1- (2 ,3 -D ihydrobenzo[b ] [1 ,4 ]d iox in -6 -y l ) -N- (3 -
fluorobenzyl)ethan-1-amine (14). Following GP1 with 1-
(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanamine (100 mg,
0.56 mmol) and 1-(bromomethyl)-3-fluorobenzene (105 mg,
0.56 mmol), the resulting product was purified via flash
chromatography (0−15% EtOAc/hexanes) to give the desired
compound 14 (35 mg, 22%). 1H NMR (400 MHz, CDCl3) δ
7.29−7.22 (m, 2H), 7.02−6.95 (m, 2H), 6.88 (d, J = 1.9 Hz,
1H), 6.86−6.79 (m, 2H), 4.26 (s, 4H), 3.69 (q, J = 6.6 Hz,
1H), 3.65−3.52 (m, 2H), 1.34 (d, J = 6.6 Hz, 3H). 13C NMR
(100 MHz, CDCl3) δ 163.26, 160.82, 143.63, 142.68, 138.11,
135.59, 130.07, 129.99, 119.78, 117.33, 115.53, 115.33, 115.12,
77.16, 64.50, 64.44, 57.02, 50.65, 24.23. HR-ESIMS (m/z):
calcd for C17H19FNO2 (M + H)
+ 288.1394; found 288.1391.
HPLC purity = 100% (Method A; tR = 9.30 min).
1- (2 ,3 -D ihydrobenzo[b ] [1 ,4 ]d iox in -6 -y l ) -N- (3 -
(trifluoromethyl)benzyl)ethan-1-amine (15). Following GP1
with 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanamine (100
mg, 0.56 mmol) and 1-(bromomethyl)-3-(trifluoromethyl)-
benzene (133 mg, 0.56 mmol), the resulting product was
purified via flash chromatography (0−15% EtOAc/hexanes) to
give the desired compound 15 (21 mg, 11%). 1H NMR (400
MHz, CDCl3) δ 7.55 (d, J = 1.9 Hz, 1H), 7.53−7.47 (m, 2H),
7.42 (t, J = 7.6 Hz, 1H), 6.90−6.79 (m, 3H), 4.26 (s, 4H),
3.75−3.62 (m, 3H), 1.37 (d, J = 6.6 Hz, 3H). HR-ESIMS (m/
z): calcd for C18H19F3NO2 (M + H)
+ 338.1323; found
338.1363. HPLC purity = 95% (Method C; tR = 6.33 min).
1- (2 ,3 -D ihydrobenzo[b ] [1 ,4 ]d iox in -6 -y l ) -N- (3 -
methoxybenzyl)ethan-1-amine (16). Following GP1 with 1-
(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanamine (100 mg,
0.56 mmol) and 1-(bromomethyl)-3-methoxybenzene (112
mg, 0.56 mmol), the resulting product was purified via flash
chromatography (0−15% EtOAc/hexanes) to give compound
16 (50 mg, 30%). 1H NMR (400 MHz, CDCl3) δ 7.23 (dd, J =
8.6, 7.6 Hz, 1H), 6.92−6.86 (m, 3H), 6.84 (d, J = 1.2 Hz, 2H),
6.81−6.76 (m, 1H), 4.25 (s, 4H), 3.81 (s, 3H), 3.73 (q, J = 6.6
Hz, 1H), 3.69−3.53 (m, 2H), 1.37 (d, J = 6.6 Hz, 3H). HR-
ESIMS (m/z): calcd for C18H22NO3 (M + H)
+ 300.1594;
found 300.15912. HPLC purity = 98% (Method A; tR = 9.41
min).
1- (2 ,3 -D ihydrobenzo[b ] [1 ,4 ]d iox in -6 -y l ) -N- (4 -
fluorobenzyl)ethan-1-amine (17). Following GP1 with 1-
(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanamine (100 mg,
0.56 mmol) and 1-(bromomethyl)-4-fluorobenzene (105 mg,
0.56 mmol), the product was purified via flash chromatography
(0−15% EtOAc/hexanes) to give the desired compound 17
(42 mg, 26%). 1H NMR (400 MHz, CDCl3) δ 7.26 (td, J =
8.0, 6.0 Hz, 1H), 7.11−7.01 (m, 2H), 6.97−6.78 (m, 4H), 4.26
(s, 4H), 3.77−3.55 (m, 3H), 1.37 (d, J = 6.6 Hz, 3H). HR-
ESIMS (m/z): calcd for C17H19FNO2 (M + H)
+ 288.1394;
found 288.1390. HPLC purity = 96% (Method C; tR = 6.38
min).
N-(4-(tert-Butyl)benzyl)-1-(2,3-dihydrobenzo[b][1,4]-
dioxin-6-yl)ethan-1-amine (18). Following GP1 with 1-(2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)ethanamine (100 mg, 0.56
mmol) and 1-(bromomethyl)-4-(tert-butyl)benzene (127 mg,
0.56 mmol), the product was purified via flash chromatography
(0−15% EtOAc/hexanes) to give the desired compound 18
(40 mg, 22%). 1H NMR (400 MHz, CDCl3) δ 7.37−7.33 (m,
2H), 7.27−7.22 (m, 2H), 6.92 (t, J = 1.2 Hz, 1H), 6.85 (d, J =
1.1 Hz, 2H), 4.27 (s, 4H), 3.74 (q, J = 6.5 Hz, 1H), 3.67−3.54
(m, 2H), 1.36−1.34 (m, 3H), 1.33 (s, 9H). HR-ESIMS (m/z):
calcd for C21H28NO2 (M + H)
+ 326.2115; found 326.2108.
HPLC purity = 96% (Method A; tR = 12.1 min).
7-(3-Fluoro-4-methoxybenzyl)-2,3,6,7,8,9-hexahydro-
[1,4]dioxino[2,3-g]isoquinoline (19). Following GP1 with
2,3,6,7,8,9-hexahydro-[1,4]dioxino[2,3-g]isoquinoline (50 mg,
0.26 mmol) and 4-(bromomethyl)-2-fluoro-1-methoxybenzene
(69 mg, 0.31 mmol), the product was purified via flash
chromatography (0−10% EtOAc/hexanes) to give the desired
compound 19 (52 mg, 60%). 1H NMR (400 MHz, CDCl3) δ
7.14 (dd, J = 12.2, 2.0 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H), 6.91
(td, J = 8.5, 1.7 Hz, 1H), 6.60 (d, J = 1.1 Hz, 1H), 6.49 (t, J =
1.0 Hz, 1H), 4.21 (d, J = 1.7 Hz, 4H), 3.88 (d, J = 1.8 Hz, 3H),
3.58 (d, J = 1.8 Hz, 2H), 3.50 (s, 2H), 2.78 (t, J = 5.9 Hz, 2H),
2.68 (t, J = 5.9 Hz, 2H). HR-ESIMS (m/z): calcd for
C19H21FNO3 (M + H)
+ 330.15; found 330.1496. HPLC purity
= 98% (Method B; tR = 4.03 min).
1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-5-fluoro-
1H-indole (20). Following GP2 with 5-fluoro-1H-indole (68
mg, 0.5 mmol), the product was purified via flash
chromatography (0−15% EtOAc/hexanes) to give the desired
compound 20 (100 mg, 71%) as a light-yellow oil. 1H NMR
(400 MHz, DMSO-d6) δ 7.55 (d, J = 3.1 Hz, 1H), 7.49−7.43
(m, 1H), 7.30 (dd, J = 9.9, 2.5 Hz, 1H), 6.94 (td, J = 9.2, 2.6
Hz, 1H), 6.79−6.74 (m, 1H), 6.70 (d, J = 7.0 Hz, 2H), 6.44
(dd, J = 3.1, 0.9 Hz, 1H), 5.27 (s, 2H), 4.17 (s, 4H). HR-
ESIMS (m/z): calcd for C17H15FNO2 (M + H)
+ 284.1081;
found 284.1077. HPLC purity = 98% (Method B; tR = 13.06
min).
1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-5-me-
thoxy-1H-indole (21). Following GP2 with 5-methoxy-1H-
indole (74 mg, 0.5 mmol), the product was purified via flash
chromatography (0−15% EtOAc/hexanes) to give the desired
compound 21 (112 mg, 76%) as a pale white solid. 1H NMR
(400 MHz, DMSO-d6) δ 7.40 (dt, J = 3.0, 0.7 Hz, 1H), 7.31
(dt, J = 8.9, 0.8 Hz, 1H), 7.02 (dd, J = 2.5, 0.6 Hz, 1H), 6.76−
6.68 (m, 2H), 6.68−6.61 (m, 2H), 6.33 (dd, J = 3.0, 0.8 Hz,
1H), 5.20 (s, 2H), 4.15 (s, 4H), 3.71 (s, 3H). HR-ESIMS (m/
z): calcd for C18H18NO3 (M + H)
+ 296.1281; found 296.1278.
HPLC purity = 99% (Method B; tR = 12.53 min).
2-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-6-(3-fluoro-4-
methoxyphenyl)pyridine (22). A suspension of (2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)boronic acid (478 mg, 2.66
mmol), 2-bromo-6-(3-fluoro-4-methoxyphenyl)pyridine (500
mg, 1.77 mmol), potassium carbonate (735 mg, 5.32 mmol),
and Pd(PPh3)4 (410 mg, 0.35 mmol) in 1,4-dioxane (15 mL)/
H2O (2 mL) was irradiated by MWs at 110 °C for 2 h. The
reaction mixture was diluted with EtOAc (10 mL) and filtered
through a short pad of silica. The filtrate was concentrated in
vacuo and purified via flash chromatography to give the desired
compound (410 mg, 69%). 1H NMR (400 MHz, CDCl3) δ
7.96 (dd, J = 12.9, 2.2 Hz, 1H), 7.85 (ddd, J = 8.5, 2.2, 1.2 Hz,
1H), 7.76−7.69 (m, 2H), 7.65−7.60 (m, 1H), 7.55 (ddd, J =
7.6, 6.7, 0.9 Hz, 2H), 7.08−6.95 (m, 3H), 4.31 (s, 4H), 3.94 (s,
3H). HRMS (m/z): calcd for C20H17FNO3 (M + H)
+
338.1187; found 338.1186. HPLC purity = 94% (Method D;
tR = 17.92 min).
2-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-6-(3-fluoro-4-
methoxyphenyl)piperidine (23). 2-(2,3-Dihydrobenzo[b]-
[1,4]dioxin-6-yl)-6-(3-fluoro-4-methoxyphenyl)pyridine 22
(360 mg, 1.07 mmol) and platinum(IV) oxide (48.5 mg,
0.21 mmol) were suspended in acetic acid (5 mL) and
degassed with argon. The reaction mixture was kept under
hydrogen pressure (65 psi) while shaking for 2 days. The
reaction was neutralized with NaOH to basic pH and extracted
with EtOAc (3 × 10 mL). The organic layer was dried over
anhydrous Na2SO4, filtered, and concentrated in vacuo. The
crude material was purified via flash chromatography to give
the desired compound 23 (21 mg, 6%). 1H NMR (400 MHz,
CD3OD) δ 7.17 (dt, J = 12.8, 1.8 Hz, 1H), 7.14−7.09 (m,
1H), 6.98 (t, J = 8.6 Hz, 1H), 6.90 (d, J = 2.1 Hz, 1H), 6.83
(dd, J = 8.4, 2.2 Hz, 1H), 6.76−6.71 (m, 1H), 4.17 (d, J = 1.6
Hz, 4H), 3.82 (d, J = 1.3 Hz, 3H), 3.74−3.68 (m, 1H), 3.66
(dd, J = 11.3, 2.4 Hz, 1H), 1.99−1.91 (m, 1H), 1.80−1.43 (m,
5H). HR-ESIMS (m/z): calcd for C20H23FNO3 (M + H)
+
344.1656; found 344.1650. HPLC purity = 92% (Method A; tR
= 10.1 min).
2- (2 ,3 -D ihydrobenzo[b ] [1 ,4 ]d iox in -6 -y l ) -4 - (4 -
me thoxypheny l ) t h i a zo l e (24 ) . 2 -B r omo - 1 - ( 4 -
methoxyphenyl)ethanone (117 mg, 0.51 mmol) and 2,3-
dihydrobenzo[b][1,4]dioxine-6-carbothioamide (100 mg, 0.51
mmol) were suspended in ethanol (3 mL) and refluxed for 4 h.
The reaction mixture was concentrated in vacuo and purified
via flash chromatography to give the desired compound 24 (82
mg, 49%). 1H NMR (400 MHz, CDCl3) δ 7.94−7.88 (m, 2H),
7.58 (d, J = 2.1 Hz, 1H), 7.53 (dd, J = 8.4, 2.1 Hz, 1H), 7.27
(s, 1H), 6.99−6.94 (m, 2H), 6.93 (d, J = 8.4 Hz, 1H), 4.31 (s,
4H), 3.86 (s, 3H). HR-ESIMS (m/z): calcd for C18H16NO3S
(M + H)+ 326.0845; found 326.0841. HPLC purity = 99%
(Method C; tR = 12.85 min).
N-(3-Fluoro-4-methoxyphenyl)-2,3-dihydrobenzo[b][1,4]-
dioxin-6-amine (28). Following GP3 with 2,3-dihydrobenzo-
[b][1,4]dioxin-6-amine 25 (160 μL, 1.3 mmol) and 4-bromo-
2-fluoro-1-methoxybenzene 27 (129 μL, 1.0 mmol), the
product was purified via flash chromatography (0−10%
EtOAc/hexanes) to give the desired compound 28 (124 mg,
45%) as a pale white solid. 1H NMR (400 MHz, CD3OD) δ
6.94−6.87 (m, 1H), 6.73−6.70 (m, 1H), 6.70−6.66 (m, 2H),
6.54−6.47 (m, 2H), 4.22−4.18 (m, 2H), 4.18−4.15 (m, 2H),
3.79 (s, 3H). HR-ESIMS (m/z): calcd for C15H15FNO3 (M +
H)+ 276.1030; found 276.1028. HPLC purity = 96% (Method
E; tR = 17.01 min).
N-(1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-3-fluoro-
4-methoxyaniline (29). Following GP3 with 1-(2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)ethanamine hydrochloride
12 (140 mg, 0.65 mmol) and 4-bromo-2-fluoro-1-methox-
ybenzene 27 (103 mg, 0.5 mmol), the product was purified via
flash chromatography (0−10% EtOAc/hexanes) to give the
desired compound 29 (80 mg, 53%) as a yellow thick oil. 1H
NMR (400 MHz, CD3OD) δ 6.81−6.69 (m, 4H), 6.29 (dd, J
= 13.8, 2.7 Hz, 1H), 6.24 (ddd, J = 8.8, 2.7, 1.3 Hz, 1H), 4.24
(q, J = 6.9 Hz, 1H), 4.18 (d, J = 0.8 Hz, 4H), 3.70 (s, 3H), 1.39
(d, J = 6.7 Hz, 3H). ESIMS (m/z): 163.08 (M − C7H7FNO)+.
HPLC purity = 95% (Method E; tR = 16.24 min).
N-(3-Fluoro-4-methoxybenzyl)-2,3-dihydrobenzo[b][1,4]-
dioxin-6-amine (30). Following GP3 with 6-bromo-2,3-
dihydrobenzo[b][1,4]dioxine 26 (108 mg, 0.5 mmol) and
(3-fluoro-4-methoxyphenyl)methanamine 9 (93 mg, 0.65
mmol), the product was purified via flash chromatography
(0−15% EtOAc/hexanes) to give the desired compound 30
(119 mg, 82%) as a light-yellow oil. 1H NMR (400 MHz,
CD3OD) δ 7.10−7.03 (m, 2H), 7.00 (t, J = 8.3 Hz, 1H), 6.57
(d, J = 8.6 Hz, 1H), 6.16 (dd, J = 8.6, 2.7 Hz, 1H), 6.12 (d, J =
2.7 Hz, 1H), 4.16−4.12 (m, 4H), 4.12−4.07 (m, 2H), 3.83 (s,
3H). HR-ESIMS (m/z): calcd for C16H17FNO3 (M + H)
+
290.1187; found 290.1185. HPLC purity = 95% (Method E; tR
= 13.14 min).
N-(1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-3-fluoro-
4-methoxybenzenesulfonamide (33). 1-(2,3-Dihydrobenzo-
[b][1,4]dioxin-6-yl)ethanamine 12 (100 mg, 0.56 mmol) and
TEA (233 μL, 1.67 mmol) were dissolved in DCM (3 mL)
and cooled to 0 °C. 3-Fluoro-4-methoxybenzene-1-sulfonyl
chloride 31 (125 mg, 0.56 mmol) was added, and the reaction
was stirred at 0 °C for 3 h. The reaction mixture was then
adsorbed onto silica gel and purified via flash chromatography
(0−25% EtOAc/hexanes) to give the desired compound 33
(102 mg, 50%). 1H NMR (400 MHz, CDCl3) δ 7.52−7.45 (m,
1H), 7.32 (dt, J = 10.6, 2.0 Hz, 1H), 6.91 (td, J = 8.3, 1.5 Hz,
1H), 6.68 (dd, J = 8.2, 1.6 Hz, 1H), 6.58−6.49 (m, 2H), 4.70
(d, J = 6.8 Hz, 1H), 4.42−4.32 (m, 1H), 4.24−4.15 (m, 4H),
3.93 (d, J = 1.6 Hz, 3H), 1.41 (dd, J = 6.9, 1.6 Hz, 3H). ESIMS
(m/z): 390.08 (M + Na)+. HPLC purity = 94% (Method D; tR
= 15.11 min).
N-(1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-3-fluoro-
4-methoxybenzamide (34). 3-Fluoro-4-methoxybenzoic acid
32 (95 mg, 0.56 mmol), 1-(2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)ethanamine (100 mg, 0.56 mmol) 12, HATU (212 mg, 0.56
mmol), and N,N-diisopropylethylamine (DIPEA; 195 μL, 1.12
mmol) were dissolved in DMF (3 mL) and stirred at room
temperature overnight. The reaction was diluted with water
(10 mL) and extracted with EtOAc (2 × 5 mL). The
combined organic layer was dried over anhydrous Na2SO4,
filtered, and concentrated in vacuo. The product was purified
via flash chromatography (0−35% EtOAc/hexanes) to give the
desired compound 34 (36 mg, 19%). 1H NMR (400 MHz,
CDCl3) δ 7.52 (q, J = 2.1 Hz, 1H), 7.50 (d, J = 1.8 Hz, 1H),
6.95 (t, J = 8.3 Hz, 1H), 6.88 (dd, J = 1.7, 0.8 Hz, 1H), 6.87−
6.82 (m, 2H), 6.14 (d, J = 7.6 Hz, 1H), 5.19 (p, J = 7.0 Hz,
1H), 4.25 (s, 4H), 3.92 (s, 3H), 1.55 (d, J = 6.9 Hz, 3H). HR-
ESIMS (m/z): calcd for C18H19FNO4 (M + H)
+ 332.1293;
found 332.1292. HPLC purity = 98% (Method D; tR = 12.91
min).
N-(1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)-1-(3-flu-
oro-4-methoxyphenyl)cyclopropan-1-amine (37). EtMgBr
(1.47 mL, 4.4 mmol) was added at −70 °C to a solution of
3-fluoro-4-methoxybenzonitrile (302 mg, 2.0 mmol) and
tetraisopropoxytitanium (651 μL, 2.2 mmol) in Et2O (10
mL) similar to a reported procedure.23 The yellow solution
was stirred for 10 min. After the solution was warmed to room
temperature for 1 h, BF3·Et2O (507 μL, 4.0 mmol) was added
to the dark brown solution. The mixture was stirred for an
additional hour; 1 N HCl (6 mL) and EtOAc (30 mL) were
added followed by NaOH (10% aqueous solution, 20 mL).
The reaction mixture was extracted with EtOAc (3 × 30 mL).
The combined organic layers were dried, filtered, and
concentrated in vacuo. The product was purified via flash
chromatography (0−50% EtOAc/hexanes) to give intermedi-
ate 1-(3-fluoro-4-methoxyphenyl)cyclopropan-1-amine 36 (92
mg, 25%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ
7.08−6.97 (m, 2H), 6.89 (t, J = 8.7 Hz, 1H), 3.87 (s, J = 0.6
Hz, 3H), 1.84 (s, 2H), 1.06−1.01 (m, 2H), 0.94−0.89 (m,
2H). ESIMS (m/z): 182 (M + H)+. Following GP4 with 1-
(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanone 35 (50 mg,
0.3 mmol), 1-(3-fluoro-4-methoxyphenyl)cyclopropanamine
36 (0.05 g, 0.28 mmol), and p-toluenesulfonic acid
monohydrate (5.2 mg, 0.03 mmol), the resulting imine was
dissolved in MeOH (2 mL) and cooled to 0 °C. NaBH4 (30
mg, 0.8 mmol) was added, and the reaction was stirred
overnight upon warming to room temperature. The reaction
solution was cooled again to 0 °C; 6 M aq. HCl was added,
and the cooling bath was removed after 30 min. After stirring
for 1 h at room temperature, the reaction mixture was basified
with 10% aq. NaOH and extracted with DCM (3 × 10 mL);
the combined organic phases were washed with brine and
dried over anhydrous Na2SO4. The solvent was removed in
vacuo and purified via flash chromatography (0−20% EtOAc/
hexanes) to give the desired compound 37 (11 mg, 12%) as a
light yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.06−6.97 (m,
2H), 6.89 (t, J = 8.5 Hz, 1H), 6.78−6.73 (m, 2H), 6.71−6.66
(m, 1H), 4.24 (s, 4H), 3.89 (s, 3H), 3.58 (q, J = 6.5 Hz, 1H),
1.21 (d, J = 6.5 Hz, 3H), 0.94 (ddd, J = 9.8, 6.5, 4.1 Hz, 1H),
0.80 (ddd, J = 9.6, 6.2, 4.2 Hz, 1H), 0.72 (ddd, J = 9.9, 6.2, 4.4
Hz, 1H), 0.69 (s, 1H). HR-ESIMS (m/z): calcd for
C20H23FNO3 (M + H)
+ 344.1656; found 344.1651. HPLC
purity = 96% (Method E; tR = 9.12 min).
2-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-N-(3-fluoro-4-
methoxybenzyl)propan-2-amine (39). To a solution of 1-
(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanone 31 (1 g, 5.6
mmol) in dry THF (10 mL) at −78 °C was added a solution of
3 M methylmagnesium bromide (2.81 mL, 8.4 mmol). The
mixture was stirred for 30 min and then continually stirred at
room temperature overnight. The cloudy yellow reaction
mixture was quenched with saturated NH4Cl and diluted with
EtOAc (12 mL) and brine (12 mL). The organic layer was
washed with water, dried over Na2SO4, and concentrated in
vacuo. The product was purified via flash chromatography (0−
10% EtOAc/hexanes) to give the tertiary alcohol intermediate
(922 mg, 85%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ
7.01 (dd, J = 2.3, 0.3 Hz, 1H), 6.95 (dd, J = 8.4, 2.3 Hz, 1H),
6.83 (dd, J = 8.4, 0.3 Hz, 1H), 4.25 (q, J = 0.6 Hz, 4H), 1.66
(s, 1H), 1.55 (s, 6H). ESIMS (m/z): 177 (M − OH)+. To a
solution of the alcohol intermediate (300 mg, 1.54 mmol) in
DCM (10 mL) was added NaN3 (319 mg, 4.91 mmol) at
room temperature under argon. The reaction mixture was
cooled to 0 °C, and a solution of TFA (324 μL, 4.2 mmol) in
DCM (1 mL) was added. The reaction was warmed to room
temperature and stirred overnight. The white precipitate
formed was filtered off, and the filtrate was concentrated in
vacuo. The product was purified via flash chromatography (0−
5% EtOAc/hexanes) to give the tertiary azide intermediate
(165 mg, 49%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ
6.97−6.94 (m, 1H), 6.91 (dd, J = 8.5, 2.3 Hz, 1H), 6.86−6.83
(m, 1H), 4.26 (s, 4H), 1.59 (s, 6H). ESIMS (m/z): 192 (M −
N2)
+. To a hydrogenation bottle was added azide intermediate
(160 mg, 0.73 mmol) in MeOH (2 mL). Under an argon
atmosphere, 10 mol % Pd/C (39 mg, 0.05 mmol) was quickly
added to the hydrogenation bottle; it was then capped and
placed on the hydrogenator. The reaction was ran at 45 psi
overnight, then filtered through Celite, rinsed well with
MeOH, and concentrated in vacuo to give the desired tertiary
amine compound 38 (133 mg, 94%) as a clear oil. 1H NMR
(400 MHz, CDCl3) δ 7.01 (d, J = 2.3 Hz, 1H), 6.97 (dd, J =
8.4, 2.3 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 4.25 (q, J = 0.7 Hz,
4H), 1.65−1.61 (m, 2H), 1.45 (s, 6H). ESIMS (m/z): 177 (M
− NH2)+. Following GP1 with 2-(2,3-dihydrobenzo[b][1,4]-
dioxin-6-yl)propan-2-amine 38 (58.0 mg, 0.3 mmol) and 3-
fluoro-4-methoxybenzyl bromide (65.7 mg, 0.300 mmol), the
product was purified via flash chromatography (0−10%
EtOAc/hexanes) to give the desired compound 39 (56 mg,
56%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.07 (dd, J
= 12.3, 2.1 Hz, 1H), 7.02−6.95 (m, 3H), 6.90−6.82 (m, 2H),
4.27 (q, J = 0.7 Hz, 4H), 3.86 (s, 3H), 3.41 (d, J = 0.7 Hz, 2H),
1.46 (s, 6H), 1.43 (s, 1H). 13C NMR (100 MHz, CDCl3) δ
153.51, 151.07, 146.23, 143.07, 141.84, 141.16, 134.68, 134.62,
123.54, 123.51, 118.85, 116.83, 115.99, 115.81, 114.98, 113.24,
113.22, 64.42, 64.37, 56.36, 56.34, 55.63, 46.64, 46.62, 29.73.
HR-ESIMS (m/z): 177.09 (M − C8H9FNO)+. HPLC purity =
97% (Method A; tR = 9.81 min).
N-(2-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)propan-2-yl)-3-
fluoro-4-methoxyaniline (40). Following GP3 with 2-(2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)propan-2-amine 38 (30 mg,
0.15 mmol) and 4-bromo-2-fluoro-1-methoxybenzene 27 (41
mg, 0.2 mmol), the product was purified via flash
chromatography (0−10% EtOAc/hexanes) to give the desired
compound 40 (17 mg, 34%) as a yellow oil. 1H NMR (400
MHz, CDCl3) δ 7.00−6.93 (m, 2H), 6.81 (d, J = 8.3 Hz, 1H),
6.67 (dd, J = 9.6, 8.7 Hz, 1H), 6.13 (dd, J = 13.7, 2.8 Hz, 1H),
6.08 (ddd, J = 8.8, 2.8, 1.3 Hz, 1H), 4.26 (s, 4H), 3.75 (s, 3H),
1.55 (s, 6H). HR-ESIMS (m/z): 177.09 (M − C7H7FNO)+.
HPLC purity = 95% (Method A; tR = 9.53 min).
HTS CPE Assay. Vero E6 cells were obtained from the
laboratory of Prof. Ralph Baric, Ph.D., at the University of
North Carolina, USA. The Vero E6 cells were grown in MEM/
10% HI fetal bovine serum (FBS)/1% Pen/Step supplemented
with 0.5 μg/mL amphotericin B and harvested in MEM/1%
PSG/1% HEPES supplemented with 5% HI FBS. Host cells
were mixed with VEEV (TC-83) at an MOI of ∼0.001,
allowing for multiple rounds of infection, which resulted in 5−
10% cell viability 72 h postinfection. A 25 μL aliquot of
infected cells (1.2 × 105 cells/mL) was added to each well of
the assay plates (384 well Corning 3712BC) predrugged with
test compounds in media (5 μL of 6× the test concentration;
the final test concentrations screened were 5 μg/mL, 10 μM,
or 10 μg/mL depending on the library source). A 25 μL
aliquot of uninfected cells was added to columns 1 and 2 of
each plate for the no virus cell controls (100% inhibition of
CPE). After incubating plates at 37 °C/5%CO2 and 90%
humidity for 72 h, 30 μL of Cell Titer-Glo (Promega) is added
to each well. Luminescence was read using a PerkinElmer
Envision reader following incubation at room temperature for
10 min to measure cell viability. The average Z′ value
calculated from 32 positive and negative controls on each of
the 672 assay plates run in the HTS was 0.8. Hit compounds
were retested at 10 concentrations in serial 2-fold dilutions
ranging from 40 to 0.8 μM (final assay concentration), and
EC50 values were calculated by nonlinear regression fit of the
data using a 4 parameter Levenberg−Marquardt algorithm
(IDBS XLfit model 205) with the minimum and maximum
parameters set at 0 and 100, respectively.
HTS Cell Viability Assay. Host cells in media are added in
25 μL aliquots (4000−6000 cells/well) to each well of the
assay plates (Corning 3712BC) predrugged with test
compounds (5 μL of 6× the test concentration in media).
Cells only (100% viability) and cells treated with hyamine at
100 μM final concentration (0% viability) served as the
negative and positive controls, respectively, for cytotoxic effect
in the assay. DMSO was maintained at 0.3% for all wells. After
incubating plates at 37 °C/5%CO2 and 90% humidity for 72 h,
30 μL of Cell Titer-Glo (Promega) was added to each well.
Luminescence was read using a PerkinElmer Envision reader
following incubation at room temperature for 10 min to
measure cell viability. Compounds were tested at 10
concentrations in serial 2-fold dilutions ranging from 40 to
0.8 μM (final assay concentration), and CC50 values were
determined by nonlinear regression fit of the data using a 4
parameter Levenberg−Marquardt algorithm (IDBS XLfit
model 205) with the minimum and maximum parameters set
at 0 and 100, respectively.
Virus Strains and Cells. Venezuelan equine encephalitis
virus TC83 (VEEVTC83) was obtained from Dr. Michael
Diamond (Washington University, St. Louis, MO). Mayaro
virusTRVL15537 (MAYVTRVL), Ross River virus (RRV), and
O’nyong nyong virus (ONNV) were obtained from Dr. Robert
Tesh (University of Texas Medical Branch-Galveston, TX).
CHIKV181/25 was obtained from Dr. Terence S. Dermody
(University of Pittsburgh, Pittsburgh, PA). All alphavirus
stocks were propagated on C6/36 cells by infecting with a low
multiplicity of infection. At 72 hpi, virus was isolated by
pelleting through a 20% sucrose cushion via ultracentrifugation
(25 000 rpm, 76 618g, 1.5 h, Beckman SW32Ti rotor). Titers
of viral stocks were determined by serial dilution plaque
titration assays on confluent monolayers of Vero cells using a
carboxy-methylcellulose overlay. At 48 hpi, cells were fixed
with 3.7% formaldehyde containing 1× phosphate buffered
saline and stained with methylene blue dye. Plaques were
counted using a dissecting microscope to determine the virus
titers.
Vero cells (ATCC CCL-81) and NHDF cells (ATCC PCS-
201-012) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing 5% or 10% fetal bovine serum
(FBS; ThermoScientific), respectively, and supplemented with
1× penicillin−streptomycin−glutamine (PSG; Life Technolo-
gies) at 37 °C in 5% CO2. Aedes albopictus mosquito C6/36
cells (ATCC CRL-1660) were cultured in 5% CO2 at 28 °C in
DMEM containing 10% FBS and 1× PSG.
Cytotoxicity Assay. Compound cytotoxicity was measured
at concentrations ranging from 100 to 0.41 μM following the
CellTiter-Glo luminescent cell viability assay protocol
(Promega). Briefly, starting at a concentration of 100 μM,
compounds were diluted 1:3 in a 96-well plate in 5% DMEM
supplemented with PSG. Diluted compound (50 μL) was
added to the wells of a 96-well black-walled plate (Corning)
seeded with 1 × 104 NHDF cells/well 1 day prior to the assay.
At 24 or 72 h after compound treatment of cells, 50 μL of
CellTiter-Glo substrate was added to each well, followed by 2
min on an orbital rocker and a 10 min incubation. The
luminescence of each well was measured using a Synergy HTX
microplate reader (Biotek, Winooski, VT). Well luminescence
was converted to percent cell viability index by dividing the
average luminescence value in the experimental wells by the
average value in the control wells containing untreated cells
and multiplying by 100. CC50 values were calculated by
nonlinear regression analysis with compound concentration in
log plotted versus cell viability using Prism v7 by GraphPad
Software Inc.
Dose Titration, Time of Addition, and Virus Titration.
Compounds were resuspended in 100% dimethyl sufloxide
(DMSO, Sigma) at a concentration of 10 mM. To produce a
10-point curve ranging from 100 to 0.19 μM, compounds were
diluted in DMEM supplemented with 5% FBS and PSG
starting at 100 μM and then diluted 1:1 to generate the
remaining dilutions. A no treatment control and DMSO
control at a concentration of 5 μL/mL were included. Diluted
compounds and controls were added to 48-well plates of
confluent NHDFs in quadruplicate, for each concentration, 1 h
prior to infection. Unless otherwise stated, cells were infected
with an MOI of 1 PFU/cell for VEEVTC83 in at least triplicate
wells in the presence of compound. At 2 hpi, infection media
were removed and plates were washed one time with PBS.
Fresh media containing compound were added to the cells.
The time of addition studies were completed by treating and
infecting cells at the indicated times. At 24 hpi, 20 μL samples
of supernatant were collected into 96-well plates and frozen at
−80 °C for later use in plaque assays to determine the levels of
infectious virus production. For the plaque assay, 10-fold serial
dilutions were made in 96-well plates and 100 μL of each
dilution was transferred into the wells of confluent monolayers
of Vero cells in a 48-well plate. At 2 hpi, cells were overlaid
with 250 μL of carboxymethylcellulose sodium salt (CMC)
made in DMEM supplemented with 5% FBS and PSG. At 48
hpi, plates were fixed with 3.7% formalin and stained with 0.4%
methylene blue dye. Plaques were counted, and data were
prepared by log transformation of compound concentration
values and normalization. IC90 values were calculated using a
nonlinear regression equation with Prism v7.
RNA Analysis by Northern Blotting. NHDF cells were
pretreated with 10 μM compound for 1 h prior to infection
with VEEVTC83 at an MOI of 5 PFU/cell. At 2 hpi, cells were
washed 1× with PBS and fresh media were added containing
compound (10 μM). At 12 hpi, total RNA was isolated from
cells using Trizol reagent (Thermo Fisher Scientific) according
to the manufacturer’s protocol. Isolated RNA was quantified
using a Nanodrop spectrophotometer. A 10 μg sample of RNA
was separated by gel electrophoresis using a 1% form-
aldehyde−agarose gel. RNA was transferred to a N+ hybond
membrane (Amsersham Biosciences) using the capillary
transfer method. After transfer, the RNA was fixed to the
membrane via UV-cross-linking. DIG-labeled probes for
Northern blots were generated by PCR amplification of a 1
kb fragment spanning the E2-6k-E1 coding region of VEEV;
cDNA from VEEVTC83 was amplified using primers flanking
the region of interest (forward primer: 5′-CTCACTACA-
CGCACGAGCTCATATC; reverse primer: 5′-CTGAGCTT-
GAGACTGTTCTGGATTG). The human β-actin DIG-
labeled probe was made from PCR amplification of DNA
from pGEM expressing human β-actin using human β-actin
specific primers (forward primer: 5′-CGCAGTTATCTAC-
AAACGGTA; reverse primer: 5′-TTTACTCTCAGGTGT-
GCGA). Probes were hybridized overnight at 68 °C in
hybridization buffer. Blots were washed twice for 5 min with a
low stringency buffer, twice with 1× SSC containing 0.1% SDS
at room temperature (rt), and twice for 15 min with 0.1× SSC
containing 0.1% SDS at 68 °C and then blocked for 3 h in
blocking solution (Roche) at rt. Anti-DIG-alkaline phosphatase
antibody was applied for 30 min at room temperature. Blots
were washed in buffer containing 0.1 M maleic acid, 0.5 M
NaCl, and 0.3% Tween 20, followed by equilibration in
detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, pH 9.5).
Antibodies were visualized using a CSPD alkaline phosphatase
substrate and visualized on CL-XPosure film (Thermo
Scientific).
Generation of Replicon Particles and Entry Assay. A
virus replicon particle expressing VRP-GFP was generated on
the basis of the Trinidad strain of VEEV (VEE 3526).21 Briefly,
replicon plasmid pVR21, containing the viral nonstructural
genes and GFP gene, was linearized with Not I and used as a
template for in vitro transcription using the Invitrogen
mMESSAGE mMACHINE T7 Transcription Kit (Fisher
Scientific) following the manufacturer’s protocol. Two helper
constructs, which express capsid and glycoproteins from VEEV
3526, were also linearized with Not I and transcribed in vitro.
10 μg of RNA from each construct was electroporated into
BHK-21 cells. At 48 h post-transfection, supernatants were
collected, clarified at 2000 rpm for 15 min, and then
ultracentrifuged at 100 000g for 12 h at 4 °C under a 20%
sucrose cushion. Pellets were resuspended in D-PBS
(Corning), aliquoted, and stored at −80 °C until further use.
VRPs were titered on Vero cells by the immunofluorescence
assay and were further confirmed to lack replicative virus as is
evident from the absence of CPE after two serial passages on
Vero cells. To identify the steps where compound 1 interferes
with VEEV replication, human embryonic kidney 293T (HEK-
293T) cells were pretreated with either compound 1 or 5 at a
concentration of 1, 5, and 10 μM or 10 μM DMSO for 1 h.
HEK-293T cells were used for this assay because they are
susceptible to VEEV infection and they transfect better than
primary human fibroblasts NHDF cells. Cells were then
infected with VRP-GFP at an MOI of 1 PFU/cell for 1 h,
washed with PBS, and replenished with growth media. At 12
hpi, cells were washed with PBS, fixed with 4% paraformalde-
hyde (PFA), and analyzed by flow cytometry for the expression
of GFP. To determine if the molecule inhibits virus replication
at the postentry step, HEK-293T cells were similarly pretreated
with the compound 1 or 5 at a concentration of 1, 5, and 10
μM or 10 μM DMSO for 1 h and then in vitro transcribed
replicon RNA (VRP-GFP) was transfected into the cells using
Lipofectamine 3000 (Fisher Scientific). At 24 h post-
transfection, cells were washed with PBS and fixed with 4%
PFA, and GFP expression was analyzed by flow cytometry.
Differences in drug efficacy of compound 1 in these studies
likely reflect differences in VEEV replication efficiency in this
cell type and the MOI utilized for these experiments.
Luciferase Assay. To identify the mechanism of action of
compound 1, two reporter viruses were generated in the VEEV
TC83 background in which NanoLuc (nLuc; 513 nt;
developed by Promega Corporation) was inserted either as
an nsP3 fusion (TC83 nsP3-nLuc) or between the capsid and
PE2 proteins (TC83-Cap-nLuc). These reporter viruses can
identify the translation of the incoming genomic RNA as well
as translated full-length progeny genomes and 26S dependent
structural genes. Vero cells (3 × 104) were plated in 24-well
plates 12 h prior to treatment with compound 1 or 5 for 1 h
prior to infection with TC83 nsP3-nLuc and TC83-Cap-nLuc
at an MOI of 5 PFU/cell. At 12 hpi, cells were washed twice
with PBS and lysed in passive cell lysis buffer (Promega). 20
μL of cell lysate was mixed with 20 μL of Nano-Glo Luciferase
Assay reagent (Promega), and the luminescence was measured
with a luminometer. The luminescence was normalized to
protein concentration as measured by the BCA protein assay
(Fisher Scientific).
Western Blotting Analysis of VEEV Proteins. Vero cells
were pretreated with either compound 1 or 5 at 1, 5, and 10
μM or DMSO 1 h prior to infection with the TC-83 strain of
VEEV at an MOI of 5 PFU/cell. At 12 hpi, cells were washed
twice with PBS and lysed in RIPA lysis buffer with protease
and phosphatase inhibitor cocktail (Roche). The total protein
in the cell lysates was quantified using the Pierce BCA protein
assay kit (ThermoFisher Scientific). Protein lysates were
analyzed by Western blotting as described previously.24 Briefly,
equal amounts of protein (50 μg) from each treatment were
separated on the Mini-PROTEAN TGX Precast gels (Bio-Rad
Laboratories, Hercules, CA) and transferred to polyvinylidene
difluoride (PVDF) membranes. Membranes were blocked with
5% nonfat dry milk in Tris-buffered saline with 0.1% Tween-20
(TBS-T) for 1 h at room temperature followed by incubation
with goat anti-VEEV capsid polyclonal antiserum (BEI
resources, Cat No. NR-9403), goat anti-VEEV glycoprotein
polyclonal antiserum (BEI resources, Cat No. NR-9404), or
mouse antihuman β-actin antibody (Santa Cruz Biotechnol-
ogy) in 1% bovine serum albumin (BSA) overnight at 4 °C.
Membranes were then washed three times with TBS-T for 10
min and incubated with IRDye 800CW Donkey anti-Goat IgG
(H + L) or IRDye 800CW Donkey anti-Mouse IgG (H + L)
(LI-COR Biosciences). After three more washings, membranes
were developed with an Odyssey CLX Imaging system (LI-
COR Biosciences).
Immunofluorescence Assay. Vero cells on coverslips
were pretreated with compound 1 or 5 or DMSO at 10 μM 1 h
prior to infection with the TC-83 strain of VEEV at an MOI of
5 PFU/cell and stained as described.25 At 12 hpi, cells were
fixed with 4% paraformaldehyde at room temperature for 2 h.
After that, cells were washed 5× with PBS−glycine (10 mM)
and incubated with primary antibody (goat anti-VEEV
glycoprotein polyclonal antiserum (BEI resources, Cat No.
NR-9404)). After an incubation with primary antibody at 37
°C for 1 h, cells were washed again 5× with PBS−glycine and
incubated with donkey anti-Goat IgG (H + L) conjugated with
alexa fluor 594 for 1 h at 37 °C. The cells were washed again
with PBS−glycine and mounted with mounting media
containing DAPI.
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multiplicity of infection; NHDF, normal human dermal
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nyong virus; RNA, ribonucleic acid; RRV, Ross River virus;
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tetrahydrofuran; TFA, trifluoroacetic acid; tR, retention time;
p-TSA, para-toluenesulfonic acid; UNAV, Una virus; VEEV,
Venezuelan Equine Encephalitis Virus; VTR, virus titer
reduction; WEEV, Western Equine Encephalitis Virus
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